AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06472414 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercise Training Sessions
Description: Participants will exercise 2-3 times/week (60 min/session), on non-consecutive days, for 6 months (weekly target of 10 kcal/kg). Blood pressure and heart rate (HR) will be measured before and after each session. During exercise, a HR chest strap (POLAR H10) will be used to monitor HR and control intensity. Aerobic prescription will be based on the baseline cardiopulmonary exercise test, each session will start with a 5'-10' minutes warm-up - low to moderate intensity \[\<40% of HR Reserve (HRR), 9-10 Rated Perceived Exertion Borg Scale (RPE)\], mobility and low impact exercises, followed by a 30'-45' minutes of combined training with an aerobic component - moderate intensity (40% to 59% of HRR; 12-14 RPE) using ergometers, aerobic exercises, walking/jogging; and a strength component - 8/10 exercises, 30-80% of 1-Repetition Maximum, 12-15 repetitions, 2 sets - ending with a 5'-10' minute cool down - static/dynamic stretching exercises for all major muscle groups.
Study NCT06472414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Training Sessions
Description: Participants will exercise 2-3 times/week (60 min/session), on non-consecutive days, for 6 months (weekly target of 10 kcal/kg). Blood pressure and heart rate (HR) will be measured before and after each session. During exercise, a HR chest strap (POLAR H10) will be used to monitor HR and control intensity. Aerobic prescription will be based on the baseline cardiopulmonary exercise test, each session will start with a 5'-10' minutes warm-up - low to moderate intensity \[\<40% of HR Reserve (HRR), 9-10 Rated Perceived Exertion Borg Scale (RPE)\], mobility and low impact exercises, followed by a 30'-45' minutes of combined training with an aerobic component - moderate intensity (40% to 59% of HRR; 12-14 RPE) using ergometers, aerobic exercises, walking/jogging; and a strength component - 8/10 exercises, 30-80% of 1-Repetition Maximum, 12-15 repetitions, 2 sets - ending with a 5'-10' minute cool down - static/dynamic stretching exercises for all major muscle groups.
Study NCT05849012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Sulfur Diet
Description: Subjects will be placed on a low sulfur diet for 8 weeks with the support of a nutritionist.~In addition, participants will be asked to complete: surveys, lactulose-mannitol test, glucose hydrogen breath test, blood samples, visceral sensation test, 24-hour urine sample for sulfate level, provide stool samples, optional colonoscopy.
Study NCT05849012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Diet
Description: Subjects will continue on their usual diet for 8 weeks. At the end of 8 weeks, if participants are interested, they will be offered treatment with low sulfur diet for 8 weeks with the support of a nutritionist.~In addition, participants will be asked to complete: surveys, lactulose-mannitol test, glucose hydrogen breath test, blood samples, visceral sensation test, 24-hour urine sample for sulfate level, provide stool samples, optional colonoscopy.
Study NCT06447129 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: An 8-week exercise program used in conservative treatment of degenerative meniscus tears will be performed.~The patients will do exercises under the control of the physiotherapist in the clinic.~The patient will perform the exercises with the verbal and visual commands of the physiotherapist.
Study NCT06447129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: An 8-week exercise program used in conservative treatment of degenerative meniscus tears will be performed.~The patients will do exercises under the control of the physiotherapist in the clinic.~The patient will perform the exercises with the verbal and visual commands of the physiotherapist.
Study NCT06447129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: The Neuromuscular Electrical Stimulation (NMES) will be applied for 20 minutes. The patient will be seated with hips and knees flexed at 90°. Electrodes will be placed on the proximal and distal ends of the vastus medialis obliquus and vastus lateralis muscles. The intensity will be increased as much as the patient can tolerate, and the patient will be asked to relax and not make voluntary muscle contractions.
Study NCT04530552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO
Study NCT04530552 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT04530552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT06226220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation
Description: Sacral neuromodulation (SNM) is a minimally invasive procedure that provides low-amplitude electrical stimulation to the S3 nerve root to improve micturition and defecation. Patients who elect to proceed with SNM undergo a trial phase to determine therapeutic response prior to placement of a permanent implantable pulse generator (IPG). A trial phase can be performed in two ways: a percutaneous nerve evaluation (PNE) or staged implantation. PNE involves the placement of a temporary wire connected to an electrode using external stimulation. It is performed in the office using local anesthesia. If the patient displays adequate improvement in symptoms (defined as >50% improvement of symptoms from baseline), a permanent lead and subcutaneous IPG are implanted in the operating room.
Study NCT06226220 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacral neuromodulation
Description: Sacral neuromodulation (SNM) is a minimally invasive procedure that provides low-amplitude electrical stimulation to the S3 nerve root to improve micturition and defecation. Patients who elect to proceed with SNM undergo a trial phase to determine therapeutic response prior to placement of a permanent implantable pulse generator (IPG). A trial phase can be performed in two ways: a percutaneous nerve evaluation (PNE) or staged implantation. PNE involves the placement of a temporary wire connected to an electrode using external stimulation. It is performed in the office using local anesthesia. If the patient displays adequate improvement in symptoms (defined as >50% improvement of symptoms from baseline), a permanent lead and subcutaneous IPG are implanted in the operating room.
Study NCT06313398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biotin-labeled red blood cells
Description: Cellular Product (patient's own red blood cells washed in Biotin and infused back to patient)
Study NCT06307743 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: rapid local ischemic postconditioning
Description: Rapid local ischemic postconditioning (RL-IPostC) is performed immediately (within 5 minutes) after revascularization. A balloon guiding catheter (BGC) positioned on ipsilateral C1 segment of internal carotid artery is inflated and deflated for the temporary occlusion of the antegrade flow.
Study NCT06470815 — intervention group
Intervention type: PROCEDURE
Intervention: Transcarotid Artery Revascularization (TCAR)
Description: Carotid artery revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
Study NCT06279650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Description: The HYlaDo intervention comprises 8 90-minute sessions. Session 1 offers psycho-education on pain and medical hypnosis. Sessions 2 to 7 offer brief introductions followed by hypnosis induction, during which the CBT elements (exposure and cognitive restructuring) to be worked on during the session are introduced. The sessions are aimed at managing: 2- anxiety and mood; 3- pain dramatization; 4- and 5- pain perception; 6- kinesiophobia; 7- future projection and resource mobilization. Session 8 provides feedback and recommendations for independent practice. Each hypnosis follows the same pattern: induction, deepening, CBT-based hypnotic work, post-hypnotic suggestions and return to wakefulness, explanations of the exercise and recommendations for independent practice.
Study NCT06279650 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education and cognitive Bahavioral therapy (CBT)
Description: The psychoeducation-CBT intervention for pain and anxiety/depression consists of 8 90-minute sessions. It has already been implemented in HMR's pain clinic, and controls both the effects of time and repetition of measures, as well as non-specific factors including expectations associated with receiving active treatment, therapeutic relationship, frequency of encounters, and participation in a manualized intervention. It is designed to inform participants about pain, its costs, neurophysiology, nature and impact. It includes general information on pain, as well as information tailored to the participants' particular type of pain. The sessions are interactive, with the therapist stimulating discussion of the educational content and its relevance to the participants' lives.
Study NCT06026111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Description: Home-based, virtually supervised, aerobic exercise intervention at a high intensity in an interval fashion.
Study NCT06026111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Description: Home-based, virtually supervised, aerobic exercise intervention at a moderate intensity in a continuous fashion.
Study NCT05843786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon gamma
Description: Daily subcutaneous administration of Interferon gamma during 5 days
Study NCT05843786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo during 5 days
Study NCT06362733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Pivotal Response Treatment for Insistence on Sameness in Autistic Youth
Description: This is a 12-week intervention program (1 hour/week) of treatment to target insistence on sameness in youth with autism spectrum disorder (ASD). Treatment will be delivered via secure telemedicine platform and consist of combination of parent-training and parent-mediated intervention with the child.
Study NCT05085990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TARA-002
Description: Phase 1b, Dose Expansion Phase: All subjects will receive 6 weekly doses of TARA-002 at the recommended Phase 2 dose (R2PD)
Study NCT05222646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Will receive single dose of 10mg of Metoclopramide intramuscularly
Study NCT05543044 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer mentor intervention
Description: Peer mentor delivered intervention for transitions to adult-oriented treatment for eating disorders
Study NCT06302660 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breath test
Description: Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of breath.
Study NCT06302660 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva sample
Description: Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of saliva.
Study NCT06302660 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of blood.
Study NCT06302660 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine sample
Description: Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of urine.
Study NCT06302660 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stool sample
Description: Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of stool.
Study NCT06302660 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Health-related Quality of life questionnaires
Description: Participants will attend an outpatient clinic and complete validated healthy-related quality-of-life questionnaires.
Study NCT05104229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81Mg Ec Tab
Description: Aspirin 81Mg Ec Tab by mouth twice daily starting the day after surgery until hospital discharge, then for 30 days
Study NCT05104229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care VTE prophylaxis
Study NCT06388954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: True Transcutaneous auricular Vagus Nerve Stimulation (TaVNS)
Description: Vagus Nerve Stimulation (VNS) consists in the activation of the Vagus nerve using electrical current, Transcutaneous auricular VNS works through the placement of noninvasive electrodes on the neck or auricle for stimulation of the auricular branch of the vagus nerve.~Transcutaneous electrical nerve stimulation (TENS) electrodes will be used to stimulate the auricular branch of the Vagus nerve, The active electrode will be placed on the cymba concha of the left ear. This reduced the risk of taVNS side eﬀect on the heart. The reference electrode will be placed outside the left ear attached to the tragus. TENS parameters used were: 30 minutes treatment time, a pulse width of 300 microseconds, pulse frequency 20 hertz and a duty cycle of 25%. The stimulation intensity was set at super-threshold levels, such as 200% of patient perceptual threshold.
Study NCT06388954 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Trancutaneous auricular Vagus Nerve Stimulation
Description: Sham transcutaneous vagal nerve stimulation will be performed by the same procedures of the study group but without electrical stimulation. The active electrodes will be attached to the left cymba conchae. The taVNS stimulator will be turned on and the stimulation intensity will be increased until the patient perceived the electrical stimulation and then the stimulator will be turned off.
Study NCT06582212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mymovesmatter mobile application
Description: Patients with Parkinson's disease will use a mobile application (Mymovesmatter) to evaluate changes in motor and non motor symptoms during their hormonal cycles.
Study NCT05291286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXQ-350
Description: BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 will be administered by intravenous (IV) infusion
Study NCT05291286 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be 0.9% normal saline of matching volume to BXQ-350 administered by intravenous (IV) infusion
Study NCT04981730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based intervention
Description: The web-based intervention participants will follow the website's orientation, the curriculum of modules, and professional feedback to complete the intervention.
Study NCT06421051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transauricular Vagal Nerve Stimulation
Description: Transauricular vagal nerve stimulation
Study NCT06421051 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transauricular Vagal Nerve Stimulation
Description: Transauricular vagal nerve stimulation
Study NCT06417775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Oral Tablets
Study NCT06417775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Ubrogepant
Description: Oral Tablets
Study NCT05005403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-514
Description: Intravenous (IV) Infusion
Study NCT05005403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: IV Infusion
Study NCT06788990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ficerafusp alfa
Description: Investigational
Study NCT06304220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cerazet
Description: Comparation of the utilization of two distinct progestogens for pituitary suppression
Study NCT06788990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA®)
Description: Immunotherapy agent used in combination with investigational agent
Study NCT05685966 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT06788990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab (KEYTRUDA®)
Description: Immunotherapy agent used in combination with investigational agent
Study NCT05152589 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: hearing test
Description: Auditory Brainstem Response (ABR) Test
Study NCT06788990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Control
Study NCT06484322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategies Empowering Activities in Everyday life (SEE 2.0)
Description: SEEs internet-based intervention process begins with supporting the client to explore the need of and readiness for changes in everyday life. Thereafter, the client is supported to self-analyse their engagement in activities in everyday life along with use of management strategies in everyday life. Next, the client takes on web- modules including short educational movies with subsequent analyses and reflections. The modules aim to support the development of self-management by improving the knowledge of how strategies and changes in daily activities can prevent disabilities and contribute to improved health. After that, the focus is on establishing an activity plan with goals and activity-based management strategies to promote an active everyday life. The clients' implementation of the plan is supported through follow-up meetings. During the whole intervention process, the client is regularly supported by an occupational therapist through feedback and online guiding dialogues.
Study NCT05923463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: precision-enhanced feedback email messages
Description: Providers receive customized messages prioritizing metrics in an optimal formatting.
Study NCT05923463 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard feedback email messages
Description: Providers receive metrics in a common format.
Study NCT05322525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON101 Cream
Description: Test drug:~1. Name: ON101~2. Dosage form: Topical cream~3. Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica~4. Dose(s): Apply 1 cc per 5 cm2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply once a day
Study NCT04851249 — intervention group
Intervention type: PROCEDURE
Intervention: Hallux Valgus - chevron osteotomy, lapidus procedure
Description: The purpose is to compare the preoperative clinical features (previous medical history, age, BMI, occupational status etc), PROMs (Manchester-Oxford Foot and ankle questionnaire, SF-36, VAS activity scale) and radiological parameters (both two and three dimensional) with the postoperative PROMs (+ likert scale) and the postoperative radiological parameters.
Study NCT04580953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardiaCareTM RR2
Description: Treatment with CardiaCareTM RR2
Study NCT06787144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELVN-001
Description: Orally once daily
Study NCT06789692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tobacco smoking substitution products
Description: Offer of preference-based smoking substitution menu, consisting of e-cigarettes or nicotine pouches or nicotine patches in addition to standard of care. This menu will be offered by the treating physician during the routine cohort visit and the participant can choose one product to test as an alternative to tobacco smoking. The products will be handed out directly after the consultation and are provided free of charge for 6 months.
Study NCT06097468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NisinZ® P
Description: NisinZ® P is an ultrapure Nisin Z concentrate produced by fermentation using the bacterium Lactococcus lactis obtained from sauerkraut
Study NCT06097468 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery (non-interventional, standard of care)
Description: Surgical removal of tumor as part of standard of care treatment
Study NCT06791486 — intervention group
Intervention type: OTHER
Intervention: AI-assisted predictive model
Description: This study utilizes an AI-assisted predictive model that analyzes multimodal data from electronic health records, including medical history, laboratory results, imaging data, and lifestyle factors, to estimate biological age. The model employs deep learning algorithms to predict biological age, compare it to chronological age, and identify early signs of age-related health risks. The intervention is not a direct treatment or procedure but aims to develop a tool for predicting biological age to help personalize care and improve long-term health outcomes.
Study NCT04573920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrasentan
Description: Film-coated tablet
Study NCT05057897 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AZD1222
Description: 10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6
Study NCT04952909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShortCut™
Description: Splitting bioprosthetic aortic valve leaflets
Study NCT06084637 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of autologous microfat
Description: A preparation of autologous microfat (5mL) will be injected intra-articularly.